Analysis seems to be in line with previous results
AstraZeneca-Oxford vaccine candidate shows average efficacy of 70.4% in pooled analysis of interim data. This confirmed in peer-reviewed data.
- 62% for those given 2 doses
- 90% efficacy for those who take half dose than a full dose
A note of caution is that the reviewers can’t assess effects in older groups.